Acute Myeloid Leukemia

Therapeutic response

Precision oncology relationships for therapeutic response involving this cancer type.

Organization(s)	Biomarker(s)	Cancer type	Therapy(ies)
FDA (1)	IDH2 p.R140Q	Acute Myeloid Leukemia	Enasidenib
FDA (1)	IDH2 p.R140L	Acute Myeloid Leukemia	Enasidenib
FDA (1)	IDH2 p.R140G	Acute Myeloid Leukemia	Enasidenib
FDA (1)	IDH2 p.R140W	Acute Myeloid Leukemia	Enasidenib
FDA (1)	IDH2 p.R172K	Acute Myeloid Leukemia	Enasidenib
FDA (1)	IDH2 p.R172M	Acute Myeloid Leukemia	Enasidenib
FDA (1)	IDH2 p.R172G	Acute Myeloid Leukemia	Enasidenib
FDA (1)	IDH2 p.R172S	Acute Myeloid Leukemia	Enasidenib
FDA (1)	IDH2 p.R172W	Acute Myeloid Leukemia	Enasidenib
FDA (2)	IDH1 p.R132C	Acute Myeloid Leukemia	Ivosidenib
FDA (2)	IDH1 p.R132G	Acute Myeloid Leukemia	Ivosidenib
FDA (2)	IDH1 p.R132H	Acute Myeloid Leukemia	Ivosidenib
FDA (2)	IDH1 p.R132L	Acute Myeloid Leukemia	Ivosidenib
FDA (2)	IDH1 p.R132S	Acute Myeloid Leukemia	Ivosidenib
EMA (1) FDA (1)	IDH1 p.R132C	Acute Myeloid Leukemia	Azacitidine, Ivosidenib
EMA (1) FDA (1)	IDH1 p.R132G	Acute Myeloid Leukemia	Azacitidine, Ivosidenib
EMA (1) FDA (1)	IDH1 p.R132H	Acute Myeloid Leukemia	Azacitidine, Ivosidenib
EMA (1) FDA (1)	IDH1 p.R132L	Acute Myeloid Leukemia	Azacitidine, Ivosidenib
EMA (1) FDA (1)	IDH1 p.R132S	Acute Myeloid Leukemia	Azacitidine, Ivosidenib
EMA (1) FDA (1) HSE (1)	FLT3-ITD	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin
FDA (1)	FLT3 p.D835Y	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin
FDA (1)	FLT3 p.D835A	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin
FDA (1)	FLT3 p.D835E	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin
FDA (1)	FLT3 p.D835H	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin
FDA (1)	FLT3 p.D835N	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin
FDA (1)	FLT3 p.D835S	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin
FDA (1)	FLT3 p.D835V	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin
FDA (1)	FLT3 p.I836del	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin
FDA (1)	CDK12 oncogenic variants	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin
FDA (1)	IDH1 p.R132C	Acute Myeloid Leukemia	Olutasidenib
FDA (1)	IDH1 p.R132G	Acute Myeloid Leukemia	Olutasidenib
FDA (1)	IDH1 p.R132H	Acute Myeloid Leukemia	Olutasidenib
FDA (1)	IDH1 p.R132L	Acute Myeloid Leukemia	Olutasidenib
FDA (1)	IDH1 p.R132S	Acute Myeloid Leukemia	Olutasidenib
FDA (1)	t(KMT2A;v)	Acute Myeloid Leukemia	Revumenib
EMA (1)	CD33 +	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Gemtuzumab ozogamicin
EMA (1) HSE (1)	FLT3-ITD	Acute Myeloid Leukemia	Gilteritinib
EMA (1) HSE (1)	FLT3 p.D835Y	Acute Myeloid Leukemia	Gilteritinib
HSE (2)	FLT3-ITD	Acute Myeloid Leukemia	Midostaurin
EMA (1) FDA (1)	FLT3-ITD	Acute Myeloid Leukemia	Quizartinib
EMA (1) FDA (1) HSE (1)	FLT3-ITD	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Quizartinib
EMA (1) FDA (1)	FLT3-ITD	Acute Myeloid Leukemia	Cytarabine, Idarubicin, Quizartinib
FDA (1)	NPM1 p.W288Cfs*12	Acute Myeloid Leukemia	Ziftomenib
FDA (1)	NPM1 p.W288Cfs*12	Acute Myeloid Leukemia	Revumenib